Abstract
Uterine leiomyomas (fibroids) are the most common solid pelvic tumor in women. They are found clinically in approximately 25% of women, and pathological serial sectioning shows that their prevalence is even higher.1 Fibroids represent the most common indication for hysterectomy for benign disease in the United States.2,3
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94: 435–438.
Lee NC, Dicker RC, Rubin GL, Ory HW. Confirmation of the preoperative diagnoses for hysterectomy. Am J Obstet Gynecol 1984; 150: 283–287.
Easterday CL, Grimes DA, Riggs JA. Hysterectomy in the United States. Obstet Gynecol 1983; 62: 201–212.
Robins SL, Cotran RS. Leiomyomata (fibromyoma). In: The Pathogenic Basis of Disease. Philadelphia: W.B. Saunders Co., 1979: 1271.
Tamaya T, Fujimoto J, Okada H. Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium. Acta Obstet Gynecol Scand 1985; 64: 307.
Sadan O, Vanidelekinge B, Van Gelderen CJ, Savage N, Becker PJ, Van Der Walt LA, Robinson M. Estrogen and progesterone receptor concentrations in leiomyomas and normal myometrium. Ann Clin Biochem 1987; 24: 263.
Pollow K, Sinnecker G, Boquoi E, Pollow B. In vitro conversion of estradiol 17ß into estrone in normal human myometrium and leiomyoma. J Clin Chem Clin Biochem 1978; 16: 493–502.
Otubu JA, Buttram VC, Besch NF, Besch PK. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982; 143: 130.
Maheux R, Lemay A, Merat P. Use of intra-nasal leuteinizing hormone-releasing hormone agonist in uterine leiomyomas. Fertil Steril 1987; 47: 229–233.
Deligdish L, Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol 1970; 23: 676–680.
Berkeley AS, DeCherney AH, Polan ML. Abdominal myomectomy and subsequent fertility. Surg Gynecol Obstet 1983; 156: 319–322.
Dicker RC, Greenspan JR, Strauss LT, Cowart MR, Scully MJ, Peterson HB, DeStefano HB, Rubin AL, Ory HW. Complications of ab-dominal and vaginal hysterectomy among women of reproductive age in the United States. The collaborative review of sterilization. Am J Obstet Gynecol 1982; 144: 841–848.
Richards DH. Depression after hysterectomy. Lancet 1973; 2: 430–433.
Buttram VC, Reiter RC. Uterine leiomyomata: Etiology, symptomatology and management. Fertil Steril 1981; 36: 433–445.
Stovall TG, Ling FW, Henry LC, Woodruff MR. A randomized trial evaluating leuprolide acetate before hysterectomy as treatment for leiomyomas. Am J Obstet Gynecol 1991; 164: 1420–1425.
Goldzieher JW, Macqueo M, Ricaud L, Aguilar JA, Canales E. Induction of degenerative changes in uterine myomas by high dosage progestin therapy. Am J Obstet Gynecol 1966; 96: 1078–1087.
DeCherney AH, Maheux R, Polan ML. A medical treatment for myomata uteri. Fertil Steril 1983; 39: 429–430.
Coutinho EM, Boulanger GA, Concalves MT. Regression of uterine leiomyomata after treatment with gestrinone, an antiestrogen, anti-progesterone. Am J Obstet Gynecol 1986; 155: 761–767.
19.Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. Br Med J 1986; 293: 359–362.
Murphy AA, Kettel LM, Morales A, Yen SSC. Response of uterine fibroids to the antipro- gesterone RU 486. A pilot study. Abstract 071, AFS, Orlando, Florida 1991.
Baird DT, Bramley TA, Hawkins TA, Lumsden MA, West CP. Effect of treatment with GnRH analogue zoladex on binding of estradiol, progesterone and epidermal growth factor to uterine fibromyomata.
Lumsden MA, West CP, Bramley T, Rumgay L, Baird DT. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypoestrogenic by continuous administration of LH RH agonist. Br J Obstet Gynec 1988; 95: 1299–1304.
Wiznitzer A, Marbach M, Hazum E, et al. Gonadotropin-releasing hormone specific binding sites in uterine leiomyomata. Biochem Biophys Res Comm 1988; 152: 1326.
Rein MS, Friedman AJ, Pandian MR, Heffner LJ. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol 1990; 76: 388–394.
Resnik R, Killam AP, Battaglia FC, Makowski EL, Meschia G. The stimulation of uterine blood flow by various estrogens. Endocrinology 1974; 94: 1192–1196.
Matta WHM, Stabile I, Shaw RW, Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist buserelin. Fertil Steril 1988; 49: 1083–1085.
Zawin M, McCarthy S, Scoutt L, Lange R, Lavy G, Vulte J, Comite F. Monitoring therapy with a gonadotropin-releasing hormone analog: Utility of MR imaging. Radiology 1990; 175: 503–506.
Benagiano G, Morini A, Abbondante A, et al. Sequential GnRH analogue (buserelin)— medroxyprogesterone acetate MPA treatment of uterine leiomyomata. In: Vickery BH, Lunenfeld B, eds. GnRH Analogues in Cancer and Human Reproduction. Lancaster: MTP Press.
Loumaye E, Naor Z, Catt KJ. Binding affinity and biological activity of gonadotropin-releasing hormone agonists in isolated pituitary cells. Endocrinology 1982; 111: 730–736.
Fraser HM. LHRH analogues: Their clinical physiology and delivery systems. In: Healy DL, ed., Balliere’s Clinical Obstetrics and Gyne-cology—International Practice and Research. Anti-Hormones in Clinical Gynecology. Vol 2. London: Balliere Tindall, 1988: 639.
Friendman AJ, Barbieri RL, Benacerraf BR, Schiff I. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil Steril 1987; 48: 560–564.
Vollenhoven BJ, Shekleton P, McDonald J, Healy DL. Clinical predictors for buserelin acetate treatment of uterine fibroids: A pro-spective study of 40 women. Fertil Steril 1990; 54: 1032–1038.
West CP, Lumsden MA, Lawson S, Williamson J, Baird DT. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): A leuteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987; 48: 45–51.
Van der Spuy ZM, Fieggan AG, Wood MJA, Pienaar CA. The short-term use of luteinizing hormone-releasing hormone analogues in uterine fibroids. Horm Res 989;32(Suppl 1 ): 137–140.
Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas ATA. Luteinizing hormone-releasing hormone agonist and uterine leiomyoma; a pilot study. Am J Obstet Gyn 1985; 152: 1034–1038.
Kessel B, Liu J, Mortola J, Berga S, Yen SSC. Treatment of uterine fibroids with agonist analogs of gonadotropin-releasing hormone. Fertil Steril 1988; 49: 538–541.
Collins RL. Treatment of symptomatic leiomyomata uteri with a long acting gonadotropin- releasing hormone agonist: Long-term follow- up. Gynecol Endocrinol (Suppl 1) 1988; 2: 89.
Andreyko JL, Blumenfeld Z, Marshall LA, Monroe SE, Hricak H, Jaffe RB. Use of an agonist analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas: Assessment by magnetic resonance imaging. Am J Obstet Gynecol 1988; 158: 903–910.
Van Leusden HAIM. Triptorelin to prevent hysterectomy in patients with leiomyomas. Lancet 1988; 2: 508–519.
Benagiano G, Primiero F, Morini A, Isidori C, Addi G, Tunner G. Multimodal pharmacological approach to the treatment of leiomyomata uteri. Gynecol Endocrinol (Suppl 2 ) 1988; 2: 50
Matta WHM, Shaw RW, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynecol 1989; 96: 200–206.
Williams IA, Shaw RW. Effect of Nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging. Eur J Obstet Gynecol Reprod Biol 1990; 34: 111–117.
Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: A double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991; 77: 720–725.
Meyer WR, Mayer AR, Diamond WP, et al. Unsuspected leiomyosarcoma: Treatment with a gonadotropin releasing hormone analogue. Obstet Gynecol 1990; 75: 529.
Benagiano A, Morini A, Aleandri V, Piccinno F, Primiero FM, Abbondante A, Elkind-Hirsch K. Sequential GnRH superagonist and medroxy-progesterone acetate treatment of uterine leiomyomata. Int J Obstet Gynecol 1990; 33: 333–343.
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention trial results. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351.
Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47–51.
Matta WH, Shaw RW, Hesp R, Katz D. Hypogonadism induced by luteinizing hormone releasing hormone analogues: Effects on bone density in premenopausal women. Br Med J 1987; 294: 1523.
Dodin S, Lemay A, Maheux R, Dumont M, Turcot-Lemay L. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991; 77: 410.
Van Leusden HAIM, Dogterom AA. Rapid reduction of uterine leiomyomas with montly injections of △-trp-GnRH. Gynecol Endocrinol 1988; 2: 45 – 51.
Comite F, Jensen P. Bone density changes associated with GnRH analogues. International Symposium on GnRH Analogues in Cancer and Human Reproduction. Geneva, Switzerland, Feb 1988.
Comite F, Jensen P, Lewis A, et al. GnRH analog therapy in endometriosis: Impact on bone mass. Society for Gynecologic Investigation Atlanta, IGA, March No. 112, 1987.
Tummon IA, Ali A, Pepping ME, Radwanska E, Binor Z, Dmowski WP. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 1988; 49: 792–796.
Bianchi G, Costantini S, Anserini P, Rovetta G, Monteforte P, Menada MV, Faga L, DeCecco L. Effects of gonadotropin-releasing hormone agonist on uterine fibroids and bone density. Maturitas 1989; 11: 179–185.
Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: Effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21 – 26.
Devogelaer JP, Huaux JP, Donnez J, et al. Differential effects of the GnRH agonist buserelin on the axial and the appendicular skeleton at different scanning sites. Preferential loss of trabecular bone. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1987. Proceedings of the International Symposium on Osteoporosis. Viborg: Norhaven Bogtrykkeri, p. 588.
Devogelaer JP, De Deuxchaisnes CN, Donnez J, Thomas K. LHRH analogues and bone loss (letter). Lancet 1987; 1: 1498.
Johansen JS, Riis BJ, Hassager C, Moer M, Jacobson J, Christiansen C. The effect of gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701–706.
Matta WHM, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypoestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol 1988;29:45 –51.
Lumsden MA, West CP, Baird DT. Goserelin therapy before surgery for uterine fibroids (letter). Lancet 1987; 1: 36–37.
Friedman AJ, Rein MS, Harrison-Atlas D, Garfield JM, Doubilet PM. A randomized, placebo controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. Fertil Steril 1989; 52: 728–733.
Healy DL, Lawson SR, Abbott M, Baird DT, Fraser HM. Toward removing uterine fibroids without surgery: Subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab 1986; 63: 619–625.
Dubuisson JB, Mandlebrot L, Lecuru F, Aubriot FX, Foulot H, Mouly M. Myomectomy by laparoscopy: A preliminary report of 43 cases. Fertil Steril 1991; 56: 827–830.
Hsueh AJW, Peck EJ, Clark JH. Progesterone antagonism of the estrogen receptor and estrogen induced uterine growth. Nature 1975; 254: 337–339.
Benagiano G, Morini A, Aleandri V, Piccinno F, Angelini R, Goldzieher JW. Sequential buserelin-medroxyprogesterone acetate treatment of leimyomata uteri. In: Brosens I, Jacobs HS, Runnebaum B, eds. LHRH Analogues in Gynecology. New Jersey: The Parthenon Publishing Group, 1990.
Friedman AJ, Barbieri RL, Doubilet PM, Fine C, Schiff I. A randomized, double-blind trial of gonadotropin-releasing hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Fertil Steril 1988; 49: 404–409.
Maheux R. The use of LHRH analogues in the treatment of leiomyoma uteri. In: Brosens I, Jacobs HS, Runnebaum B, eds. LHRH Analogues in Gynecology. New Jersey: The Parthenon Publishing Group, 1990.
Friedman AJ. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: A pilot study. Fertil Steril 1989; 51: 526–528.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Philosophe, R. (1993). GnRH Agonists in the Treatment of Fibroids. In: Seibel, M.M., Bernstein, J. (eds) Technology and Infertility. Springer, New York, NY. https://doi.org/10.1007/978-1-4613-9205-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-4613-9205-7_17
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4613-9207-1
Online ISBN: 978-1-4613-9205-7
eBook Packages: Springer Book Archive